NEW YORK (GenomeWeb News) – Molecular diagnostics firm IntegraGen said today that it has acquired the exclusive rights to use a specific microRNA as a biomarker for predicting patient outcomes in metastatic colorectal cancer.

The license was obtained from the Paris Descartes University, INSERM, the Centre National de la Recherche Scientifique, and the Assistance Publique — Hopitaux de Paris. Terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.